Prosecution Insights
Last updated: October 25, 2026

Shanghai Curegene Pharmaceutical Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Shanghai Curegene Pharmaceutical Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner in 1 art unit, creating a single examination channel.

CORNET, JEAN P is the listed examiner and the busiest examiner, with 1 pending matter. Counsel can tailor claim amendments and prior-art analysis to that examiner’s treatment of the pending file.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CORNET, JEAN P 1 41.9% +47.2%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18832936 PHARMACEUTICAL COMPOSITION OF ANTIPLATELET DRUG, AND USE THEREOF CORNET, JEAN P —

Top Art Units

Art UnitApps
1628 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18832936 PHARMACEUTICAL COMPOSITION OF ANTIPLATELET DRUG, AND USE THEREOF CORNET, JEAN P 1628 §103 Non-Final OA — Pending Jul 25, 2024

Managing Shanghai Curegene Pharmaceutical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Shanghai Curegene Pharmaceutical Co. Ltd. have?

Shanghai Curegene Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Shanghai Curegene Pharmaceutical Co. Ltd. applications?

Jean P Cornet has the most, with 1 of Shanghai Curegene Pharmaceutical Co. Ltd.'s pending office actions.

What technology area are Shanghai Curegene Pharmaceutical Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month